Ali Behbahani - Net Worth and Insider Trading
Ali Behbahani Net Worth
The estimated net worth of Ali Behbahani is at least $205 Million dollars as of 2023-03-30. Ali Behbahani is the 10% Owner of Mirum Pharmaceuticals Inc and owns about 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) stock worth over $98 Million. Ali Behbahani is the 10% Owner of Akouos Inc and owns about 4,294,207 shares of Akouos Inc (AKUS) stock worth over $57 Million. Ali Behbahani is also the Director of Adaptimmune Therapeutics PLC and owns about 19,500,000 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $21 Million. Besides these, Ali Behbahani also holds Trevi Therapeutics Inc (TRVI) , Black Diamond Therapeutics Inc (BDTX) , Metacrine Inc (MTCR) , Marker Therapeutics Inc (MRKR) , Regulus Therapeutics Inc (RGLS) , Genocea Biosciences Inc (GNCAQ) . Details can be seen in Ali Behbahani's Latest Holdings Summary section.
Transaction Summary of Ali Behbahani
Ali Behbahani Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ali Behbahani owns 20 companies in total, including Metacrine Inc (MTCR) , CRISPR Therapeutics AG (CRSP) , and Genocea Biosciences Inc (GNCAQ) among others .
Click here to see the complete history of Ali Behbahani’s form 4 insider trades.
Insider Ownership Summary of Ali Behbahani
|Ticker||Comapny||Transaction Date||Type of Owner|
|MTCR||Metacrine Inc||2020-09-15||10 percent owner|
|CRSP||CRISPR Therapeutics AG||2016-10-18||director|
|GNCAQ||Genocea Biosciences Inc||2018-02-08||director|
|ADAP||Adaptimmune Therapeutics PLC||2016-01-01||director|
|AKUS||Akouos Inc||2020-06-25||10 percent owner|
|OYST||Oyster Point Pharma Inc||2019-10-30||director|
|TRVI||Trevi Therapeutics Inc||2019-05-07||10 percent owner|
|BDTX||Black Diamond Therapeutics Inc||2020-01-29||director & 10 percent owner|
|RGLS||Regulus Therapeutics Inc||2018-06-01||10 percent owner|
|MIRM||Mirum Pharmaceuticals Inc||2019-07-17||10 percent owner|
|MRKR||Marker Therapeutics Inc||2018-10-17||director|
|XFOR||X4 Pharmaceuticals Inc||2018-06-01||10 percent owner|
|SVRA||Savara Inc||2021-03-15||10 percent owner|
|UTRS||Minerva Surgical Inc||2021-10-21||director|
|BHG||Bright Health Group Inc||2021-06-24||10 percent owner|
|GLUE||Monte Rosa Therapeutics Inc||2021-06-23||director & 10 percent owner|
Ali Behbahani Latest Holdings Summary
Ali Behbahani currently owns a total of 9 stocks. Among these stocks, Ali Behbahani owns 4,186,243 shares of Mirum Pharmaceuticals Inc (MIRM) as of July 22, 2019, with a value of $98 Million and a weighting of 47.63%. Ali Behbahani owns 4,294,207 shares of Akouos Inc (AKUS) as of June 30, 2020, with a value of $57 Million and a weighting of 27.8%. Ali Behbahani also owns 19,500,000 shares of Adaptimmune Therapeutics PLC (ADAP) as of January 24, 2020, with a value of $21 Million and a weighting of 10.07%. The other 6 stocks Trevi Therapeutics Inc (TRVI) , Black Diamond Therapeutics Inc (BDTX) , Metacrine Inc (MTCR) , Marker Therapeutics Inc (MRKR) , Regulus Therapeutics Inc (RGLS) , Genocea Biosciences Inc (GNCAQ) have a combined weighting of 14.5% among all his current holdings.
Latest Holdings of Ali Behbahani
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
|MIRM||Mirum Pharmaceuticals Inc||2019-07-22||4,186,243||23.36||97,790,636|
|ADAP||Adaptimmune Therapeutics PLC||2020-01-24||19,500,000||1.06||20,670,000|
|TRVI||Trevi Therapeutics Inc||2022-04-11||11,370,376||1.80||20,466,677|
|BDTX||Black Diamond Therapeutics Inc||2020-02-03||3,448,757||1.86||6,414,688|
|MRKR||Marker Therapeutics Inc||2021-03-16||1,071,429||0.85||910,715|
|RGLS||Regulus Therapeutics Inc||2020-12-04||645,106||0.82||529,180|
|GNCAQ||Genocea Biosciences Inc||2022-05-25||0||0.00||0|
Holding Weightings of Ali Behbahani
Ali Behbahani Form 4 Trading Tracker
According to the SEC Form 4 filings, Ali Behbahani has made a total of 1 transactions in Mirum Pharmaceuticals Inc (MIRM) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Mirum Pharmaceuticals Inc is the acquisition of 450,000 shares on July 22, 2019, which cost Ali Behbahani around $7 Million.
According to the SEC Form 4 filings, Ali Behbahani has made a total of 1 transactions in Akouos Inc (AKUS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Akouos Inc is the acquisition of 588,235 shares on June 30, 2020, which cost Ali Behbahani around $10 Million.
According to the SEC Form 4 filings, Ali Behbahani has made a total of 2 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Adaptimmune Therapeutics PLC is the acquisition of 7,500,000 shares on January 24, 2020, which cost Ali Behbahani around $5 Million.More details on Ali Behbahani's insider transactions can be found in the Insider Trading History of Ali Behbahani table.
Insider Trading History of Ali Behbahani
Ali Behbahani Trading Performance
GuruFocus tracks the stock performance after each of Ali Behbahani's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ali Behbahani is -4.94%. GuruFocus also compares Ali Behbahani's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ali Behbahani within 3 months outperforms 6 times out of 14 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ali Behbahani's insider trading performs compared to the benchmark.
Performance of Ali Behbahani
Average Relative Return
|1 Month||3 Months||6 Months||1 Year||2 Years||3 Years|
|Relative Return to S&P 500(%)||2.95||-4.56||-17.53||-57.95||-54.35||-46.21|
Ali Behbahani Ownership Network
Ownership Network List of Ali Behbahani
Ownership Network Relation of Ali Behbahani
Ali Behbahani Owned Company Details
What does Metacrine Inc do?
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.
Who are the key executives at Metacrine Inc?
Ali Behbahani is the 10 percent owner of Metacrine Inc. Other key executives at Metacrine Inc include 10 percent owner Braden Michael Leonard , Chief Business Officer Michael York , and EVP & Gen. Counsel & Secretary Catherine Chai-zon Lee .
Metacrine Inc (MTCR) Insider Trades Summary
Over the past 18 months, Ali Behbahani made 1 insider transaction in Metacrine Inc (MTCR) with a net sale of 497,270. Other recent insider transactions involving Metacrine Inc (MTCR) include a net purchase of 2,510,570 shares made by Braden Michael Leonard , a net sale of 425,353 shares made by Preston Klassen , and a net sale of 615,702 shares made by Venbio Global Strategic Fund, L.p. .
In summary, during the past 3 months, insiders sold 487,659 shares of Metacrine Inc (MTCR) in total and bought 0 shares, with a net sale of 487,659 shares. During the past 18 months, 5,623,539 shares of Metacrine Inc (MTCR) were sold and 2,510,570 shares were bought by its insiders, resulting in a net sale of 3,112,969 shares.
Metacrine Inc (MTCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Metacrine Inc Insider Transactions
Ali Behbahani Mailing Address
Above is the net worth, insider trading, and ownership report for Ali Behbahani. You might contact Ali Behbahani via mailing address: 5425 Wisconsin Ave, Chevy Chase Md 20815.